课题基金 / 基金详情

Galectin-3介导的多核型髓源抑制细胞在宫颈癌淋巴结转移前微环境中的作用及其机制研究

批准号:
81872128
项目类别:
面上项目
资助金额:
54.0 万元
负责人:
刘军秀
依托单位:
学科分类:
肿瘤微环境
结题年份:
2022
批准年份:
2018
项目状态:
已结题
项目参与者:
何科、黄佳明、刘田雨、尚春亮、杜奇鞘、廖远东、刘盼

项目摘要

结项摘要

项目成果

刘军秀的其他基金

相似基金

相关文献

中文摘要
淋巴结转移是宫颈癌患者致死的主要原因。研究发现多核型髓源抑制细胞(PMN-MDSCs)可构筑转移前微环境而促进肿瘤转移。然而,PMN-MDSCs在宫颈癌淋巴结转移前微环境中的作用尚未阐明。我们预实验发现,肿瘤分泌因子Galectin-3在宫颈癌淋巴结转移前微环境中高度表达并能够募集PMN-MDSCs。前期研究也证明,Galectin-3与宫颈癌淋巴结转移高度相关并可明显促进宫颈癌转移。由此,我们推测:Galectin-3可能通过募集PMN-MDSCs促宫颈癌淋巴结转移前微环境形成,进而定向转移。因此,本项目拟进一步阐明Galectin-3通过integrin αVβ3/c-Src/STAT3招募PMN-MDSCs促进淋巴血管新生及构筑免疫抑制的宫颈癌淋巴结转移前微环境的机制。本研究从转移前微环境角度揭示宫颈癌淋巴结定向转移的新机制,为宫颈癌患者提供潜在的淋巴结转移预警分子及精准治疗靶点。
英文摘要
Lymph node metastasis contributes largely to the mortality of cervical cancer patients. Researchers have discovered that polymorphonuclear myeloid-derived suppressor cells(PMN-MDSCs) could promote tumor metastasis via forming pre-metastatic niche. However, the effect of PMN-MDSCs on forming pre-metastatic niche in cervical cancer lymph nodes has not been revealed. Our pre-experiments demonstrated that tumor-secreted factor Galectin-3 was significantly upregulated in pre-metastatic niche in cervical cancer lymph nodes and could recruit PMN-MDSCs. Our previous study also showed that Galectin-3 was corelated to lymph node metastasis in cervical cancer patients and dramatically promoted cervical cancer metastasis. Therefore, we assume that Galectin-3 may form pre-metastatic niche in cervical cancer lymph nodes through recruiting PMN-MDSCs, promoting cervical cancer lymph node metastasis. On the basis of this hypothesis, the present project intends to further clarify the mechanism of Galectin-3 recruiting PMN-MDSCs through activating integrin αVβ3/c-Src/STAT3 pathway, promoting lymphogenesis and forming immune suppressive pre-metastatic niche in cervical cancer lymph nodes. This project would discover novel mechanism of oriented lymph node metastasis in cervical cancer from the perspective of pre-metastatic niche, providing potential diagnosis and treatment target for cervical cancer patients with lymph node metastasis.
淋巴结转移是宫颈癌患者致死的主要原因。研究发现多核型髓源抑制细(PMN-MDSCs) 可构筑转移前微环境而促进肿瘤转移。然而,PMN-MDSCs在宫颈癌淋巴结转移前微环境中的作用尚未阐明。.本项目阐明了肿瘤来源分泌分子Galectin-3 可经循环系统进入淋巴结内,通过 integrin αVβ3/c-Src/STAT3通路招募 PMN-MDSCs 并使其持续增殖,促进局部淋巴血管新生及构筑免疫抑制的转移前微环境,进而招募更多的宫颈癌细胞发生淋巴结定向转移。本研究从转移前微环境角度揭示宫颈癌淋巴结定向转移的新机制,为宫颈癌患者提供潜在的淋巴结转移预警分子及精准治疗靶点。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
A Cholesterol Homeostasis-Related Gene Signature Predicts Prognosis of Endometrial Cancer and Correlates With Immune Infiltration.
胆固醇稳态相关基因特征可预测子宫内膜癌的预后并与免疫浸润相关
DOI: 10.3389/fgene.2021.763537
发表时间: 2021
期刊: Frontiers in genetics
影响因子: 3.7
作者: [Chen Y, Lee K, Liang Y, Qin S, Zhu Y, Liu J, Yao S]
通讯作者: Yao S
High Expression of Integrin α3 Predicts Poor Prognosis and Promotes Tumor Metastasis and Angiogenesis by Activating the c-Src/Extracellular Signal-Regulated Protein Kinase/Focal Adhesion Kinase Signaling Pathway in Cervical Cancer
整合素α3的高表达通过激活宫颈癌中的c-Src/细胞外信号调节蛋白激酶/粘着斑激酶信号通路来预测不良预后并促进肿瘤转移和血管生成
DOI: 10.3389/fonc.2020.00036
发表时间: 2020-02-14
期刊: FRONTIERS IN ONCOLOGY
影响因子: 4.7
作者: [Du, Qiqiao, Wang, Wei, Yao, Shuzhong]
通讯作者: Yao, Shuzhong
17β-Estradiol nongenomically induces vascular endothelial H2S release by promoting phosphorylation of cystathionine γ-lyase
17β-雌二醇通过促进胱硫醚γ-裂合酶的磷酸化非基因组诱导血管内皮H2S 释放
DOI: 10.1074/jbc.ra119.008597
发表时间: 2019
期刊: JOURNAL OF BIOLOGICAL CHEMISTRY
影响因子: 4.8
作者: [Xu Xingyan, Yan Qing, Liu Xiaoyun, Li Ping, Li Xiaosa, Chen Yiwen, Simoncini Tommaso, Liu Junxiu, Zhu Dongxing, Fu Xiaodong]
通讯作者: Fu Xiaodong
The voltage-gated sodium channel Nav1.7 associated with endometrial cancer
电压门控钠通道 Nav1.7 与子宫内膜癌相关
DOI: 10.7150/jca.31544
发表时间: 2019-08
期刊: Journal of Cancer
影响因子: 3.9
作者: [Junxiu Liu, Hao Tan, Wancai Yang, Shuzhong Yao, Liang Hong]
通讯作者: Liang Hong
6
    CCL22/CCR4介导的淋巴窦内皮细胞定向诱导宫颈癌淋巴结转移的作用及其机制研究
    • 批准号:
      82072884
    • 项目类别:
      面上项目
    • 资助金额:
      56.0万元
    • 批准年份:
      2020
    • 负责人:
      刘军秀
    • 依托单位:
    Galectin-3激活ezrin蛋白促宫颈癌转移的作用及其信号机制研究
    • 批准号:
      81502226
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      18.0万元
    • 批准年份:
      2015
    • 负责人:
      刘军秀
    • 依托单位:
    国内基金
    海外基金